Mutational biosynthesis has been shown to be a valuable technique for preparing new antibiotics. Recently, several groups'`') have reported an isolation of 2-deoxystreptamine (DOS) idiotrophic mutants from various aminoglycoside-producing organisms and a preparation of new aminoglycoside antibiotics using this technique.
Micromonospora sagamiensis was isolated by NARA et al.") as a producer of sagamicin, a novel broad spectrum aminoglycoside antibiotic. In the present investigation, the authors attempted to utilize the DOS idiotrophic mutants for preparation of new mutasynthetic antibiotics. When streptamine, a structural analog of DOS, was fed to the mutants, a new antibiotic, 2-hydroxysagamicin, was produced. In this communication, isolation, identification and biological properties of the 2-hydroxysagamicin are described.
M. sagamiensis KY 11505, a sagamicin producing strain, and its mutants were maintained on agar slants of a seed medium. After two stages of cultivation in a seed medium (3 days and 1 day, respectively), the seed medium was transferred to a fermentation medium. Fermentation was conducted at 30°C for 7 days. The composition of the seed medium was (per liter): Stabilose K (soluble starch) 20 g, glucose 5 g, peptone 5 g, yeast extract 5 g, meat extract 3 g and calcium carbonate 2 g. The fermentation medium consisted of (per liter): Stabilose K 40 g, soybean meal 10 g. Pharmamedia (cottonseed flour) 20 g, corn oil I g, casein 5 g, phytate (1 Ca, 2 Mg) 2 g, FeSO47H2O 150 mg, MgSO4•7H2O 500 mg and KH2PO4 250 mg.
M. sagamicnsis KY 11505 was treated with Nmethyl-N'-nitro-N-nitrosoguanidine (NTG) at a concentration of I mg/ml for 20 minutes. The NTG treated cells were plated on agar plates of the fermentation medium, and incubated at 30°C for 7 days. The plates were overlaid with soft agar seeded with Esherichia coli KY 8301. After incubation at 37°C for overnight, mutants showing no inhibition zone were selected and transferred to the agar plates of the seed medium supplemented with 25 ,ug/ml of sagamicin to eliminate the test organism. The mutants were cultured in 10 ml of the production medium, supplemented with or without 50 jig/ml of DOS. After incubation for 7 days sagamicin production was examined.
Antibiotics were detected by bioautography against Bacillus subtilis KY 4273 after paper chromatography (PPC) or silica gel thin-layer chromatography (TLC). PPC was developed on Toyo No. 51 paper using the lower phase of chloroform -methanol -17% ammonium hydroxide (2: 1: 1 v/v). TLC was developed on Merck silica gel 60 TLC plate in the lower phase of chloroform -methanol -conc. ammonium hydroxide (1: 1: 1 v/v). The amount of antibiotics were determined by fluorometric measurements of 4-chloro-7-nitrobenzo-2-oxa-1,3-diazol (NBD chloride) according to the procedure of A number of non-sagamicin-producing mutants were derived from the sagamicin producing strain KY 11505. Four mutants, which were able to produce sagamicin when DOS was supplemented in the production medium, were selected as DOS idiotrophs. An unknown antibacterial compound was detected when three of the DOS idiotrophs were cultivated in the fermentation medium supplemented with streptamine. One mutant, KY 11525, was found to be the best strain to convert streptamine to the unknown antibiotic (named HSGM).
In order to obtain mutants possessing higher activity of the biotransformation of streptamine to HSG M, mutant KY 1 1 525 was mutated further with NTG. Colonies, showing larger inhibition zones against E. coli when grown on the production agar plates containing 25 ug/ml of streptamine, were selected as desired mutants. Biotransformation activity of a selected mutant, designated KY 11530, was approximately three times higher than that of KY 11525 (Fig. 1) .
The antibiotic HSG M was isolated from the OF ANTIBIOTICS VOL. XXXV NO. 1 fermentation broth of KY 11530. The mutant was grown in 150 liters of the fermentation medium supplemented with 50 Fag/ml of streptamine. The fermentation broth was harvested at 116 hours, and pH was adjusted to 2.0 with cone. sulfuric acid. After filtration, the filtrate was neutralized and applied to ion-exchange chromatography (Amberlite IRC-50, NH4+ form).
The column was eluted with 2 N ammonium hydroxide. Crude antibiotic was obtained from the eluates. Further purification was achieved via Amberlite CG-50 (NH4+ form) column chromatography.
The column was eluted with gradients of ammonium hydroxide, ranging from 0.1 to 1.0 normal. Fractions containing HSGM were combined, concentrated and lyophilized to obtain a crude of HSGM. The crude was further purified by silica gel column chromatography (Mallinkrodt silica gel G) using solvent system of chloroform -methanol -conc. ammonium hydroxide (5: 1: 1 v/v).
The compound thus obtained showed the following physicochemical properties: m.p. 102-112°C (dec.); [a]25D+158' (c 0.5, H2O); IR (KBr) 3350, 2940, 1580, 1480, 1380, 1345, 1050 and 1020 cm-1; Anal. Calcd. for C20H41N5O8 • H2O; C, 48.28, H, 8.71, N, 14.72; Found.; C, 48.07, H, 8.78, N, 14.65 ; mass spectrum (m/z) 479 (M+), 436, 366, 362, 349, 338, 321, 320, 207, 179, 161, 160 and 143, PMR (D2O, pD Table 1 together with those of sagamicin and streptamine. These data indicate that the structure of HSGM is 2-hydroxysagamicin.
2-Hydroxysagamicin
was tested against a number of Gram-positive and Gram-negative organisms (Table 2) . Compared with sagamicin, 2-hydroxysagamicin was slightly less potent against sagamicin-sensitive organisms but more potent against some sagamicin-resistant strains such as E. coli KY 8536, which is known to possess gentamicin 2"-adenylating enzyme. The acute (intravenous) toxicity (LD50) of 2-hydroxysagamicin was compared with sagamicin and gentamicin C complex, and it was determined that the toxicity of 2-hydroxysagamicin was onefourth to one-fifth as compared to those of Sagamicin or gentamicin C complex (Table 3) . Machida-shi, Tokyo, Japan (Received September 24, 1981) 
